Published in J Clin Invest on May 01, 2006
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet (2008) 7.05
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
Osteoprotection by semaphorin 3A. Nature (2012) 3.40
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Dimorphic effects of Notch signaling in bone homeostasis. Nat Med (2008) 2.82
Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev (2008) 2.64
Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol (2009) 2.50
Adipogenesis and WNT signalling. Trends Endocrinol Metab (2008) 2.37
Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol (2010) 2.06
miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem (2010) 2.05
Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res (2012) 2.01
Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol (2013) 2.01
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Mechanical signals as anabolic agents in bone. Nat Rev Rheumatol (2010) 1.95
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci U S A (2008) 1.86
BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development (2008) 1.86
Wnt/beta-catenin signaling in adipogenesis and metabolism. Curr Opin Cell Biol (2007) 1.84
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A (2007) 1.77
Bone mass is inversely proportional to Dkk1 levels in mice. Bone (2007) 1.71
Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene (2011) 1.66
Gpr177, a novel locus for bone mineral density and osteoporosis, regulates osteogenesis and chondrogenesis in skeletal development. J Bone Miner Res (2013) 1.64
Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell (2011) 1.63
Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci (2007) 1.61
Beta-catenin levels influence rapid mechanical responses in osteoblasts. J Biol Chem (2008) 1.60
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One (2008) 1.60
Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One (2008) 1.60
Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One (2007) 1.56
Lower vitamin E serum levels are associated with osteoporosis in early postmenopausal women: a cross-sectional study. J Bone Miner Metab (2013) 1.55
Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res (2010) 1.54
MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther (2009) 1.54
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation. Scientifica (Cairo) (2013) 1.51
The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int Immunopharmacol (2010) 1.50
Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet (2012) 1.49
Notch and the skeleton. Mol Cell Biol (2009) 1.49
Mechanical loading regulates NFATc1 and beta-catenin signaling through a GSK3beta control node. J Biol Chem (2009) 1.49
Wnt signaling in bone metabolism. J Bone Miner Metab (2009) 1.48
Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther (2007) 1.47
Copy number variation of the APC gene is associated with regulation of bone mineral density. Bone (2012) 1.46
Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density. Mol Cell Biol (2008) 1.41
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum (2008) 1.36
Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition. J Clin Invest (2012) 1.35
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood (2007) 1.33
Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology (2012) 1.32
GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One (2007) 1.29
Mechanical signal influence on mesenchymal stem cell fate is enhanced by incorporation of refractory periods into the loading regimen. J Biomech (2010) 1.29
Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab (2008) 1.28
N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation. Mol Cell Biol (2008) 1.27
Non-canonical Wnt signaling and N-cadherin related beta-catenin signaling play a role in mechanically induced osteogenic cell fate. PLoS One (2009) 1.26
The Interplay between the bone and the immune system. Clin Dev Immunol (2013) 1.26
Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis. J Biol Chem (2010) 1.25
Maternal obesity, inflammation, and fetal skeletal muscle development. Biol Reprod (2009) 1.25
Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis (2013) 1.25
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol (2013) 1.23
High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: the MOST study. Ann Rheum Dis (2010) 1.23
Obesity reduces bone density associated with activation of PPARγ and suppression of Wnt/β-catenin in rapidly growing male rats. PLoS One (2010) 1.20
Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer (2008) 1.19
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res (2011) 1.19
Unravelling the molecular control of calvarial suture fusion in children with craniosynostosis. BMC Genomics (2007) 1.18
Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One (2012) 1.17
Origin matters: differences in embryonic tissue origin and Wnt signaling determine the osteogenic potential and healing capacity of frontal and parietal calvarial bones. J Bone Miner Res (2010) 1.17
Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet (2009) 1.14
Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia (2014) 1.13
TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation. Bone Res (2015) 1.12
Mechanical activation of β-catenin regulates phenotype in adult murine marrow-derived mesenchymal stem cells. J Orthop Res (2010) 1.12
The WNT inhibitor Dickkopf 1 and bone morphogenetic protein 4 rescue adipogenesis in hypertrophic obesity in humans. Diabetes (2012) 1.11
Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr (2009) 1.11
The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol (2010) 1.11
WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am J Pathol (2008) 1.09
Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int (2012) 1.08
Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum (2012) 1.08
Activation of canonical wingless-type MMTV integration site family (Wnt) signaling in mature adipocytes increases beta-catenin levels and leads to cell dedifferentiation and insulin resistance. J Biol Chem (2010) 1.08
Growth factor control of bone mass. J Cell Biochem (2009) 1.07
Functional relationships between genes associated with differentiation potential of aged myogenic progenitors. Front Physiol (2010) 1.06
Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer (2013) 1.05
Wnt/beta-catenin inhibits dental pulp stem cell differentiation. J Dent Res (2008) 1.05
Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol (2012) 1.05
Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol (2009) 1.04
mTORC2 regulates mechanically induced cytoskeletal reorganization and lineage selection in marrow-derived mesenchymal stem cells. J Bone Miner Res (2014) 1.04
Missense polymorphisms of the WNT16 gene are associated with bone mass, hip geometry and fractures. Osteoporos Int (2013) 1.04
Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab (2010) 1.03
Mutation of Prkar1a causes osteoblast neoplasia driven by dysregulation of protein kinase A. Mol Endocrinol (2007) 1.03
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt/beta-catenin signaling. J Bone Miner Res (2010) 1.02
The functions and possible significance of Kremen as the gatekeeper of Wnt signalling in development and pathology. J Cell Mol Med (2007) 1.01
Distinct functions of Sox2 control self-renewal and differentiation in the osteoblast lineage. Mol Cell Biol (2011) 1.00
Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J (2011) 0.99
The molecular mechanism behind bone remodelling: a review. Clin Oral Investig (2009) 0.99
Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation. PLoS One (2010) 0.99
Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma (2011) 0.98
A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer (2007) 0.98
Sclerostin is a direct target of osteoblast-specific transcription factor osterix. Biochem Biophys Res Commun (2010) 0.98
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics. Stem Cells Int (2013) 0.98
N-cadherin negatively regulates osteoblast proliferation and survival by antagonizing Wnt, ERK and PI3K/Akt signalling. PLoS One (2009) 0.98
Synergistic inhibition of Wnt pathway by HIF-1α and osteoblast-specific transcription factor osterix (Osx) in osteoblasts. PLoS One (2012) 0.97
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One (2010) 0.97
Perspectives on cancer stem cells in osteosarcoma. Cancer Lett (2012) 0.97
Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. J Biol Chem (2008) 0.97
The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol (2004) 24.63
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Wnt signaling: a common theme in animal development. Genes Dev (1997) 12.94
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
Linking colorectal cancer to Wnt signaling. Cell (2000) 11.58
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38
Inhibition of adipogenesis by Wnt signaling. Science (2000) 9.72
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell (1982) 9.29
Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science (1996) 9.12
Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell (2005) 8.16
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell (2005) 6.90
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol (2002) 6.20
Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature (2002) 5.61
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 5.56
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest (2004) 5.29
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Lack of beta-catenin affects mouse development at gastrulation. Development (1995) 4.95
Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol (2003) 4.70
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem (2002) 4.40
Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol (2000) 4.36
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Regulation of Wnt signaling during adipogenesis. J Biol Chem (2002) 3.94
Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development (2004) 3.89
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
Wnt signaling in osteoblasts and bone diseases. Gene (2004) 3.72
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
The ovariectomized rat model of postmenopausal bone loss. Bone Miner (1991) 3.38
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet (2000) 3.33
BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res (2003) 3.32
Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity (2000) 3.19
The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol (2004) 3.09
The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol (2003) 3.06
Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet (2003) 2.86
MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem (2003) 2.78
Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet (2004) 2.70
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A (2005) 2.67
Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology (2002) 2.50
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res (2004) 2.46
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2004) 2.44
Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem (2004) 2.32
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
SFRP1 regulates the growth of retinal ganglion cell axons through the Fz2 receptor. Nat Neurosci (2005) 2.19
Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet (2005) 2.10
Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem (2002) 2.05
Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol (2005) 2.00
Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol (2004) 1.95
Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone (2000) 1.93
beta-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion. Development (1999) 1.89
The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol (2004) 1.77
Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem (2003) 1.76
The significance of the Wnt pathway in the pathology of human cancers. Pathology (2004) 1.76
Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol (2002) 1.75
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res (2005) 1.73
Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem (2005) 1.71
Reciprocal roles of MSX2 in regulation of osteoblast and adipocyte differentiation. J Biol Chem (2004) 1.64
Notch 1 impairs osteoblastic cell differentiation. Endocrinology (2003) 1.57
Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone (2005) 1.55
The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem (2005) 1.54
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res (2005) 1.51
Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet (2004) 1.49
Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res (2004) 1.45
Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res (2006) 1.44
How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann N Y Acad Sci (2005) 1.41
Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci (2002) 1.39
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun (2005) 1.37
Wnt5b partially inhibits canonical Wnt/beta-catenin signaling pathway and promotes adipogenesis in 3T3-L1 preadipocytes. Biochem Biophys Res Commun (2005) 1.37
Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun (2004) 1.28
Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol (1998) 1.26
Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone (2002) 1.22
Stem cell characteristics of human trabecular bone-derived cells. Bone (2002) 1.21
Interconversion potential of cloned human marrow adipocytes in vitro. Bone (1999) 1.21
Comprehensive microarray analysis of bone morphogenetic protein 2-induced osteoblast differentiation resulting in the identification of novel markers for bone development. J Bone Miner Res (2002) 1.19
Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets (2005) 1.13
Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. J Biol Chem (2005) 1.10
Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology (2005) 1.04
Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1/2 mesenchymal cells. Endocrinology (2003) 1.04
Alterations of beta-catenin pathway in non-melanoma skin tumors: loss of alpha-ABC nuclear reactivity correlates with the presence of beta-catenin gene mutation. Am J Pathol (2003) 1.01
Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab (2005) 1.00
Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone (2005) 0.99
Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem (2007) 2.69
Wnt/beta-catenin signaling in adipogenesis and metabolism. Curr Opin Cell Biol (2007) 1.84
Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res (2006) 1.44
Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition. J Clin Invest (2012) 1.35
Critical roles for the TSC-mTOR pathway in β-cell function. Am J Physiol Endocrinol Metab (2009) 1.20
Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem (2005) 1.15
New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology (2003) 1.10
On the role of FOX transcription factors in adipocyte differentiation and insulin-stimulated glucose uptake. J Biol Chem (2009) 1.02
Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem (2007) 0.99
Physical dissection of the CCAAT/enhancer-binding protein alpha in regulating the mouse amelogenin gene. Biochem Biophys Res Commun (2007) 0.93
Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation. Exp Cell Res (2008) 0.92
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. J Med Chem (2005) 0.91
Hyperphagia and obesity in female mice lacking tissue inhibitor of metalloproteinase-1. Endocrinology (2008) 0.91
Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats. Am J Physiol Endocrinol Metab (2007) 0.90
A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology (2005) 0.89
DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids. BMC Womens Health (2007) 0.87
Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther (2004) 0.84
Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene. Mol Pharmacol (2005) 0.84
Follistatin: a novel therapeutic for the improvement of muscle regeneration. J Pharmacol Exp Ther (2014) 0.83
Benzothiophene and naphthalene derived constrained SERMs. Bioorg Med Chem Lett (2004) 0.83
A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia. J Bone Miner Res (2010) 0.80
Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res (2002) 0.80
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety. Bioorg Med Chem Lett (2007) 0.80
Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther (2004) 0.80
Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs. ACS Med Chem Lett (2012) 0.77
Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats. J Bone Miner Metab (2005) 0.77
Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology (2011) 0.77
A selective estrogen receptor modulator for the treatment of hot flushes. J Med Chem (2006) 0.76
B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens. Bioorg Med Chem Lett (2003) 0.75